Metal transporter SLC39A14/ZIP14 modulates regulation between the gut microbiome and

host metabolism

Trista L. Thorn[1#], Samuel B. Mitchell[1#], Yongeun Kim[1], Min-Ting Lee[1], Janine M. C. Comrie[1],

Elizabeth L.Johnson[1], Tolunay B. Aydemir[1*]

Division of Nutritional Sciences, Cornell University, Ithaca, 14853 NY

[#]Equally contributed

*Corresponding author

Key Words: Zinc, zinc transporter, gut microbiome, metabolomics, intestine

Abstract

Zinc (Zn) plays a critical role in maintaining intestinal homeostasis by regulating intestinal

epithelial cells, host immune cells, and gut microbiome community composition. Deletion of metal

transporter *Slc39a14/Zip14* causes spontaneous intestinal permeability with low-grade chronic

inflammation, mild hyperinsulinemia, and greater body fat with insulin resistance in adipose,

suggesting a role for ZIP14-mediated intestinal metal transport in regulating both intestinal

homeostasis and systemic metabolism. Here, we showed the function of ZIP14-mediated Zn

transport in the gut microbiome composition and how ZIP14-linked changes to gut microbiome

community composition are correlated with changes in host metabolism. Deletion of *Zip14*

generated Zn-deficient epithelial cells and luminal content in the entire intestinal tract; reduced

bacterial diversity and *Saccharomyces cerevisiae* (*S. cerevisiae*) overgrowth; altered host

metabolome; and shifted host energy metabolism toward glucose utilization. This work provides

evidence for the regulation of gut microbiome composition, host metabolome, and energy

metabolism by metal transporter ZIP14.

Significance

Intestinal permeability, gut dysbiosis, and Zn dyshomeostasis are emerging signatures of

inflammatory bowel diseases and metabolic disorders such as type-2-diabetes and obesity. Zn

deficiency is a common clinical finding among these diseases. Zn is essential for the regulation

of the intestinal epithelial cells, host immune cells, and the gut microbiome. Transporter-mediated

mobilization of Zn plays a critical role in maintaining intestinal homeostasis by facilitating the

targeted tissue/cell-specific function. However, studies are lacking in linking transporter-mediated

Zn mobilization, gut microbiome, host's intestinal health, and metabolism. Using the systems-level

approach, this study revealed novel findings that deletion of *Slc39a14/Zip14* resulted in altered intestinal Zn homeostasis, gut microbiome composition, host metabolome and energy metabolism.

Introduction

The essential trace metal Zn is the second most abundant metal in the body, with diverse and indispensable catalytic, structural, and regulatory functions [1]. Zn transporters maintain Zn homeostasis by facilitating the cellular and subcellular distribution of Zn to and within tissues. Two families of metal transporters, SLC39A/ZIP1-14 (Zrt-Irt-like proteins) and SLC30A/ZnT1-10 (Zn transporter), have opposing functions. ZIP family transporters are responsible for the transport of metals into the cytoplasm from the extracellular space and within the lumen of intracellular compartments. ZnT family transporters transport metals from the cytoplasm to either extracellular space or intracellular compartments. Intestinal Zn transport is central to both intestinal and systemic Zn homeostasis. Zn is absorbed mainly by the function of apically localized Zn transporter, ZIP4 [2–4]. On the basolateral side, ZnT1 and, ZIP5 and ZIP14 are proposed to transport Zn from the enterocyte into the circulation and from circulation to enterocytes, respectively [5,6]. Metallothioneins and the ZnT2, ZnT5A, ZnT6, ZnT7, ZIP7, and ZIP14 transporters provide intracellular Zn movement [6–9].

Emerging evidence suggests that Zn transporter-mediated mobilization of Zn plays a critical role in maintaining intestinal homeostasis by facilitating the targeted tissue/cell-specific function. Zn is essential for the regulation of the intestinal epithelial cells, host immune cells, and intestinal commensal bacteria [10]. Mice lacking ZIP4 in the intestinal epithelial cells showed loss of Zn in Paneth cells with impaired proliferation and epithelial architecture [11]. Deleting ZIP7 in the intestinal epithelial cells in mice caused defects in stem cell survival, the proliferation of crypts, and resolving endoplasmic reticulum stress [12]. ZnT2 is expressed on the secretory granules in Paneth cells, promotes the accumulation of zinc, and regulates the secretion of antimicrobial molecules [13]. Genome-wide association studies revealed an association between a variant of Zn transporter ZIP8 and type of inflammatory bowel disease (IBD), Crohn's disease (CD) with altered gut microflora [14]. Intestinal permeability and inflammation are signatures of IBD. In a humanized mouse model of the *ZIP8* variant, enhanced disease susceptibility was reported in chemically induced colitis [15,16].

We have previously shown that deletion of *Zip14*, the phylogenetically closest relative of *Zip8* [17], induced spontaneous intestinal permeability with low-grade chronic inflammation (metabolic

endotoxemia), enlarged islets with mild compensatory hyperinsulinemia, and greater body fat with

insulin resistance in adipose tissue [6,18–20]. Besides Zn, ZIP14 also transports manganese and iron

[21]. We have previously shown that intestinal manganese elimination was impaired in *Zip14* KO

mice [22,23]. Here we present our novel findings on the function of ZIP14-mediated Zn transport in

intestinal tissue, microbial profile, and how ZIP14-linked changes in gut microbiome and

metabolites modulate host metabolism.

Results

Ablation of *Zip14* alters gastrointestinal Zn homeostasis. We first examine the effect of the

Zip14 deletion on Zn homeostasis in the entire intestinal tract using microwave plasma atomic

emission spectrometry (MP-AES). In the *Zip14* KO mice, Zn concentrations were lower in the

proximal and distal intestine and the colon tissue (Fig. 1A). The total intestinal content is

composed of both unabsorbed dietary Zn and Zn from endogenous sources, including

transporter-mediated transepithelial flux of Zn in the serosal to the mucosal direction. We

collected total intestinal content and separated it into two phases by centrifugation. Luminal

content (supernatant) represents ionic and protein-bound Zn, and digesta (pellet) represents the

unavailable Zn for host absorption [24]. Both luminal content and digesta had decreased

concentrations of Zn in the *Zip14* KO (Fig. 1B). These data collectively suggested that in the

absence of basolaterally localized ZIP14, Zn transport was impaired in serosal to mucosal

direction, resulting in a chronic Zn deficiency in the entire GI tract's tissue, luminal content, and

digesta. Zn absorption occurs throughout the intestinal tract as a function of Zn transporters. Since

the highest Zn absorption occurs in the proximal intestine, we measured the abundance of known

intestinal Zn transporters from isolated enterocytes. We observed more pronounced changes in

the female mice. Compared to WT, the abundance of apical Zn importer ZIP4 and basolateral Zn

exporter ZnT1 in *Zip14* KO mice was increased and decreased, respectively (Fig. 1C), supporting

the Zn-deficient conditions in the enterocytes of *Zip14* KO mice. However, these changes were

not sufficient to compensate for the deficiency caused by the absence of ZIP14.

Ablation of *Zip14* modulates gut microbiome, and ZIP14-shaped microbiome can influence

intestinal permeability and metabolic phenotypes in the host. Intestinal barrier function and

consequent metabolic alterations are regulated by dynamic and reciprocal interactions among the

intestinal microbiota, epithelium, and immune system [25]. Dietary metals are important factors

influencing the intestinal microbiome [26], as evidenced by the observations that metal availability

is crucial for the outcome of host-pathogen interactions. However, much less is known about the

effects of dietary metals on commensal bacteria. A limited number of studies have demonstrated

that both Zn deficiency and excess can influence the composition of the gut microbiome.
However, it is largely unknown whether Zn transporters regulate the gut microbiome through
modulating luminal Zn levels. Due to impaired Zn transport (serosal to mucosal), *Zip14* deletion
results in lower Zn levels in the gastrointestinal lumen than those in WT mice (Fig. 1B). We
hypothesized that a low Zn environment would affect the composition of the gut microbiome. To
test this hypothesis, we determined microbiome community composition using 16S rRNA gene
sequencing from fecal pellets of *Zip14* KO versus WT mice. We found significantly lower
microbiome α-diversity in WB-KO mice when compared to WT mice (Fig. 2A). This suggests that
the presence of certain taxa may be reliant on intestinal luminal concentrations of Zn. To better
understand which taxa might be susceptible to Zn concentrations in the lumen of the intestine, we
looked for differential abundances of taxa between the microbial communities of *Zip14* KO and
WT mice (Fig. 2B). We found a decreased abundance of Bacteriodaceae and Clostridiaceae
families and increased abundance of Ruminococcaceae families (Fig. 2C), all of which have been
observed in IBD patients as well [27,28]. To better understand how ZIP14-mediated changes in
microbiome community composition may function to alter host phenotypes, we transplanted
microbiome-depleted mice with fecal contents from *Zip14* KO and WT mice (Fig. 3A). Following
the fecal transplant, we have conducted a permeability assay using FITC-Dextran gavage. We
found significantly higher levels of FITC-Dextran in the serum of mice that received the fecal slurry
from *Zip14* KO mice (Fig. 3B), indicating that the ZIP14-shaped microbiome contributed to the
progression of intestinal permeability. Furthermore, the mice that received the fecal slurry from
Zip14 KO were mildly hypoglycemic (Fig. 3C) with significantly greater % body fat (Fig. 3D) and
lower % lean mass (Fig. 3E), recapitulating the metabolic phenotype of *Zip14* KO mice [20].
Collectively these data indicated that the ZIP14-shaped microbiome could influence metabolic
phenotypes in the host.

Saccaramicea cerevisiae (S. cerevisiae) overgrowth may contribute to intestinal
permeability in Zip14 KO mice. The gut microbiota produces a broad range of metabolic
products that impact host biology. To identify the host and microbial-originated metabolites in WT
and KO mice serum, we conducted untargeted metabolomics using Gas chromatography (GC)
coupled to time-of-flight mass spectrometry (TOF-MS). Principal component analysis (PCA) of
overall serum samples showed that metabolite abundance in *Zip14* KO mice significantly differed
from WT mice (Fig. 4A), indicating that the *Zip14* KO group could be distinguished from WT
according to their different metabolic profiles. Metabolites with a fold change of >1.5 and p-value
< 0.05 were considered significantly different (Fig. 4B). The serum concentration of 11 identifiable
metabolites varied significantly between WT and WB-KO (Fig. 4B, C). Serum adenosine,

serotonin, β-sitosterol, creatinine, N-acetyl-D-tryptophan, and saccharic acid were significantly greater, and only linoleic acid was significantly lower in the serum of *Zip14* KO mice (Fig. 4C).

The upregulated metabolite, N-acetyl-D-tryptophan, in the serum of *Zip14* KO mice could be unique to *S. cerevisiae* in the gut due to the production of a unique enzyme acting on D-amino acids, D-amino acid N-acetyltransferase [29,30]. We hypothesized that the Zn deficient gut in the *Zip14* KO mice with lower bacterial α-diversity could provide the opportunity for yeast overgrowth. Our qPCR results revealed a greater amount of *S. cerevisiae* DNA in the feces of WB-KO mice when compared to their controls (Fig. 4D). To investigate the direct effect of the gut microbiome on the metabolic phenotype of *Zip14* KO mice, we conventionalized antibiotics (abx)-treated WT mice with fecal slurry from either WT (WTCv) or *Zip14* KO (KOCv) mice. We measured *S. cerevisiae* DNA following conventionalization. The KOCv mice had a greater amount of S. cerevisiae; however, it did not reach the statistical significance ($p < 0.07$) (Fig. 4D). To understand the effect of *S. cerevisiae* on the increased intestinal permeability phenotype of WB-KO mice, the 'mice's drinking water was supplemented with the antifungal drug fluconazole for ten days. We found a significant reduction in plasma FITC-Dextran levels when WB-KO mice were treated with fluconazole, suggesting that *S. cerevisiae* overgrowth along with reduced bacterial diversity in the WB-KO contributed to the development of intestinal permeability.

Host energy metabolism is shifted towards continuous utilization of glucose as an energy source in *Zip14* KO mice. To assist in the biological interpretation of our metabolomics data, we conducted pathway and enrichment analyses using MetaboAnalyst [31] to explore whether significantly differing metabolites belong to a common pathway. There was an enrichment of significantly differing compounds in several metabolic pathways (Fig. 5A). Among them, the Tricarboxylic Acid Cycle (TCA) cycle pathway had the most significant impact score. TCA cycle intermediate metabolites, citric acid, α-ketoglutaric acid, fumaric acid, and malic acid were significantly upregulated in the serum of *Zip14* KO mice. Of note, a-ketoglutarate, fumaric acid, and malic acid are also responsible for the "alanine, aspartate, and glutamine metabolism [32]. Disease signature analysis was conducted using metabolite sets reported in human blood. In agreement with the presence of intestinal permeability and low-grade chronic inflammation in *Zip14* KO mice, the top signatures were septic shock and diabetes (Fig. 5B).

Despite the increased intestinal permeability, low-grade chronic inflammation, and insulin resistance in adipose, *Zip14* KO mice do not develop hyperglycemia. In addition, our metabolomics data revealed the most significant impact score was on TCA cycle (Fig. 5A), collectively suggesting that *Zip14* deletion may cause a shift in host energy metabolism. To

quantify these observed effects on whole-body metabolism, we conducted metabolic phenotyping
by using a Comprehensive Laboratory Animal Monitoring System (CLAMS). In the light cycle,
oxygen consumption levels (Fig. 6A), carbon dioxide production (Fig. 6B), and respiratory
exchange ratio (Fig. 6C) were greater in the *Zip14* KO mice than WT. These data suggested that
glucose was preferentially used as an energy source in the *Zip14* KO mice. This may partially
explain the prevention of hyperglycemia phenotype. Next, we fed mice with HFD for 16 weeks to
force fatty acids (consumption of excess). At the end of the study, fasting blood glucose levels
were elevated in HFD fed WT mice, but there was no increase in the HFD-fed *Zip14* KO mice,
even though both WT and KO had an equal increase in percent body fat in the HFD fed group
(data not shown).

Discussion

In this study, we showed that metal transporter Slc39a14/Zip14 regulates intestinal Zn
homeostasis and gut microbiome composition, resulting in altered host metabolism. Deletion of
the host gene encoding metal transporter, *Slc39a14/Zip14,* generated Zn-deficient epithelial and
luminal content in the entire intestinal tract; reduced microbial diversity; altered host metabolome;
and; shifted host energy metabolism toward glucose utilization (Fig. 7). To our knowledge, this is
the first investigation that links the function of a mammalian metal transporter to gut microbiome
composition, host serum metabolites, and energy metabolism.

Our previous studies showed localization of ZIP14 both to the basolateral side of the enterocyte
and endosomes [6]. In the *Zip14* KO mice, increased endosomal Zn concentrations suggested that
Zn was entrapped in these compartments and generated Zn-deficient enterocytes. Here we
showed that deletion of *Zip14* caused a deficiency in the intestinal tissue and the luminal content
(Fig. 1A, B). These mice consumed a standard chow diet, and there was no difference in food
consumption (data not shown). Therefore, low intestinal and luminal Zn suggested that Zn
transport in serosal to mucosal direction was impaired in addition to endosomal entrapment in the
absence of basolaterally localized ZIP14.   ZIP4 is an apically localized Zn transporter and is
responsible for the absorption of Zn. It is known to be upregulated during Zn deficiency to increase
Zn absorption [33]. ZnT1 on the basolateral side of the intestine was proposed to facilitate Zn
transport from enterocytes to blood [8]. ZnT1 is also regulated by Zn status [5]. It was shown that
during Zn deficiency, ZnT1 was downregulated to retain Zn in the cells. Upregulation of ZIP4 and
downregulation of ZnT1 in isolated enterocytes from *Zip*14 KO mice further supported the Zn-
deficient environment.

ZIP14, besides Zn, can transport manganese and iron [21]. We have previously shown that Zn and

manganese homeostasis were altered in *Zip14* KO mice at a steady-state [18,20,23,34], while ZIP14-

related alterations in iron transport were largely observed in iron overload [35]. Our current (Fig. 1)

and previous results confirmed that both Zn and manganese transport in serosal to mucosal

direction was impaired when *Zip14* was deleted [23,34]. Since Zn, iron, and manganese are essential

for microbial growth, the changes that we observe in gut microbiome composition could be caused

by either Zn or Mn deficient intestine of *Zip14* KO mice. Manganese deficiency in humans is

extremely rare [36,37]. However, a rare genetic mutation in metal transporter, *ZIP8*, causes

manganese deficiency with enhanced susceptibility to dextran sulfate sodium-induced injury [15].

Contrary to manganese, Zn deficiency is recognized by WHO as a major global risk factor for

disease mortality and morbidity [38]. Importantly, Zn deficiency induces diarrhea and increases the

risk of gastrointestinal diseases [39,40]. Zn deficiency is found in IBD patients, and Zn

supplementation studies have shown improved disease outcomes [10]. However, human studies

linking Zn, Zn transporters, gut microbiome composition, and intestinal health are lacking. In

animal models, both Zn excess and deficiency were shown to modulate the microbiome profile.

High dietary Zn in mice reduced the diversity of the gut microbiome community[41], while in piglets,

it caused either no change or increased microbiota diversity of ileal digesta and decreased

microbiota diversity of the colonic digesta based on the dose and duration of Zn supplementation

or the growth phase of the animals [42]. A less diverse cecal microbiome composition was detected

in gallus gallus in response to chronic dietary Zn deficiency [43], supporting our finding of lower

bacterial α-diversity in the Zn-deficient intestine of *Zip14* KO mice.

The gut microbiome consists of bacteria, viruses, protozoa, and fungi in the gastrointestinal tract.

The gut microbiota produces a broad range of metabolic products that impact host biology by

acting on cells within the gastrointestinal tract or entering circulation and affecting distal sites

within the body [44,45]. Among the upregulated metabolites in the serum of *Zip14* KO mice (Fig. 3),

N-acetyl-D-tryptophan, serotonin, and creatinine levels were shown to be different between germ-

free and conventional mice [46], suggesting microbial origin/contribution. Enteric bacteria or yeast

can generate tryptophan metabolites such as serotonin and N-acetyl-tryptophan [47,48]. While either

host or microbiome could make serotonin, N-acetyl-D-tryptophan could be unique to

Saccharomyces cerevisiae (*S. Cerevisiae*) in the gut due to the production of a unique enzyme

acting on D-amino acids, D-amino acid N-acetyltransferase [29,30]. Lower bacterial diversity in the

gut of *Zip14* KO mice could provide an opportunity for *S. cerevisiae* overgrowth. Of note, yeast

cells survive during Zn deficiency due to multiple homeostatic and adaptive strategies [49].

Increased intestinal permeability is observed both in Zn deficiency and inflammatory bowel

disease (IBD) [10]. Furthermore, Zn deficiency [50] and *S. cerevisiae* overgrowth [51] have been shown
in IBD. Interestingly, serotonin was also shown to be upregulated in Crohn's disease [52]. These
are, collectively, in agreement with the phenotype of *Zip14* KO mice with intestinal permeability
and low-grade chronic inflammation.

Here we found a shift in energy metabolism towards continuous glucose utilization as an energy
source with significantly greater TCA cycle intermediate metabolites in the serum of *Zip14* KO
mice. We have previously shown that in the absence of *Zip14*, hepatic glucose uptake was
increased along with greater glycogen stores [53] suggesting a greater amount of glucose available
for energy production. The liver may have two ways of responding to this: increasing inefficient
metabolism (Fig. 5-increased TCA cycle metabolites) and exporting these calories in the form of
fat for deposition in peripheral tissues [20]. Energy metabolism is also affected by inflammation.
During chronic inflammation, adaptive immune cells, specifically T lymphocytes, go through
metabolic reprogramming in favor of oxidative phenotype [54], in agreement with low-grade chronic
inflammation and increased TCA cycle intermediates in *Zip14* KO mice. We have previously
shown mitochondrial localization of ZIP14 in hepatocytes [18]. In addition to metabolic
reprogramming in adaptive immune cells of *Zip14* KO mice, the shift in energy metabolism could
also be due to ZIP14-mediated regulation of mitochondrial metal concentration and the function
of corresponding metalloenzymes. It is important to acknowledge that further studies with
tissue/cell type-specific conditional *Zip14* KO mice along with dietary interventions for Zn and
manganese are warranted to test these possible roles for ZIP14.

Methods

Animals and treatments

Animals. Heterozygous (*Zip14+/-)* mice are a generous gift of Dr. Robert J. Cousins. Heterozygous
Zip14+/- on the mixed background of C57BL6 and129S5 mice were bred to obtain homozygous
whole-body (WB) *Zip14* KO (*Zip14-/-)* and WT (*Zip14+/+)* mice [55]. The mice were maintained using
standard rodent husbandry and received a commercial, irradiated chow diet (Harlan Teklad 7912;
Indianapolis, IN, with 60 mg Zn/kg as ZnO) and tap water. Age-matched mice from both sexes
were used as young adults (8–16 wk of age). Euthanasia was through exsanguination by cardiac
puncture under isoflurane anesthesia. Protocols were approved by the Cornell University
Institutional Animal Care and Use Committees. *Metabolic phenotyping.* Metabolic parameters of
the mice were measured by the Comprehensive Laboratory Animal Monitoring System (CLAMS)
by using Promethion (Sable Systems). Mice were transferred to the CLAMS metabolic cages and

allowed to acclimate for 2-3 days with free access to food and water. Following the acclimation,
measurements of VO_2 and VCO_2 gas exchanges and food and water consumption were collected
for five days. The data were analyzed using Expedata software system (v1.9.27), Macro
interpreter (v2.40), and then CalR software (v.1.2). **Body composition**. Measurements were
conducted in awake animals by time-domain nuclear magnetic resonance using the Minispec
LF65 Body Composition Mice Analyzer. **Fasting blood glucose**. Following overnight fasting,
blood glucose levels were measured by tail bleeding using the OneTouch® Ultra Blood glucose
monitoring system. **Antibiotics treatment**. Antibiotics (Abx) (Ampicillin 1 g/L, neomycin 1 g/L,
gentamycin 500 mg/L; penicillin 100U/L, vancomycin hydrochloride 1g/L, metronidazole 500mg/L)
were given in the drinking water, ad libitum as described previously [56,57] for three weeks. Abx
water was replaced with control water 4 hours before fecal transplant. **Anti-fungal treatment**.
Drinking water was supplemented with fluconazole (0.5 mg/mL, Sigma) for ten days [58,59]. **Fecal**
transplant. Fecal pellets were collected from co-caged WT and WB KO mice to prepare the fecal
slurry. 0.2 g of the fecal pellet was homogenized in 1mL of phosphate-buffered saline (PBS) using
bullet blender (Next Advance). Following centrifuging at 800 x g for 3 min and filtering by 30 μm
cell strainer, antibiotics-treated mice were inoculated for three consecutive days with 0.2 ml of the
fecal slurry [57,60]. Following conventionalization, metabolic phenotypes were assessed weekly by
measuring fasting blood glucose and body composition by NMR. At the end of the three weeks,
blood and tissue were collected for further biochemical analysis. **Permeability Assay**. Following
morning fasting (removal of food and water for 4 hours), mice were be given FITC-dextran (60
mg/100 g FITC-dextran 4) (Sigma-MW 3000-5000) via oral gavage. Blood was collected into
EDTA tubes by cardiac puncture to obtain plasma at two hours post-gavage. FITC-dextran levels
in plasma were measured fluorometrically at 485 nm emission/528 nm excitation.

Analytical methods

Metal Assays. The entire excised small intestine was cut into two sections as proximal (the first
11cm) and distal (rest) and perfused with a metal chelating buffer (10 mM EDTA, 10 mM HEPES,
and 0.9% $NaCl_2$) (equal volume/section). Similarly, the colon was excised and perfused with the
above buffer. The contents of the intestine and colon were centrifuged at 3000xg to obtain the
lumen (supernatant) and digesta (pellet). Aliquots of tissue, lumen, digesta, and the fecal pellets
were digested at 95°C overnight in HNO_3 to measure metal concentrations using Microwave
Plasma-Atomic Emission Spectrometry (MP-AES). Normalization was to tissue weight or volume
(intestinal contents).

Gut microbiome and serum metabolite profiling

Fresh fecal pellets were collected from mice that were co-caged for one month prior. **DNA**
extraction and sequencing. DNA samples were extracted from the mice fecal samples using
DNeasy PowerSoil Kit (QIAGEN, Inc.) according to the manufacturer's instruction. Region V4 of
the 16S rRNA gene was amplified using the universal primers 515F and GoLay-barcoded 806R
and the PCR program as previously described[61]. Samples were amplified in duplicate with the
following thermocycler protocol: hold at 94°C for 3 min; 30 cycles of 94°C for 45 s, 50°C for 1 min,
72°C for 1.5 min; and hold at 72°C for 10 min, and the duplicate final amplified products were
pooled. Amplicons were further purified using Mag-Bind® RxnPure Plus (Omega Bio-tek, Inc.)
and quantified with NanoDrop 2000 spectrophotometer (Thermo Fisher Scientific), and 150 ng of
amplicons from each sample were pooled and paired-end sequenced (2 x 250bp) on an Illumina
MiSeq instrument. **16S rRNA gene sequencing analysis**. Reads were demultiplexed using
QIIME v1.9.1 (split_libraries_fastq.py) before denoising and processing with Divisive Amplicon
Denoising Algorithm 2 (DADA2) [62]. Taxonomy was assigned by mapping with the Greengenes
16S rRNA Gene Database [63]. The QIIME output data was then imported to RStudio (Version
1.0.136) with the Bioconductor package phyloseq [64] to normalize and plot the input data. All
statistical analyses were done in R using the vegan [65] and DESeq2 [66]. A Benjamini–Hochberg
FDR of 0.01 was used as the cutoff for statistical significance for heatmap plotting unless
otherwise noted. **Saccharomyces cerevisiae detection**. For isolating fungal DNA, an equal
amount of colon digesta from each mouse were suspended in 50 mM Tris buffer (pH 7.5)
supplemented with one mM EDTA, 0.2% b-mercaptoethanol and 1000 units/ml of lyticase
(Sigma), incubated at 37°C for 30 min to disrupt fungal cells as described [58,59] prior to processing
through the QIAamp Fast DNA Stool Mini Kit (Qiagen). The quantitative PCR (qPCR) reactions
with an equal amount of DNA were set up using power track SYBR green master mix and run in
Roche Lightcycler 480-II RT-PCR system. The S. cerevisiae-specific primer sequences were
forward 5-AGGAGTGCGGTTCTTTG-3 and reverse 5-TACTTACCGAGGCAAGCTACA-3 [67].
Serum untargeted metabolomics profiling. Gas chromatography (GC) coupled to time-of-flight
mass spectrometry (TOF-MS) was performed using Gerstel CIS4 –with dual MPS Injector/ Agilent
6890 GC-Pegasus III TOF MS by UC Davis West Coast Metabolomics Center. Statistical and
pathway analyses were performed using MetaboAnalyst 5.0 [31]. Data were normalized to the
median to account for variance between samples and generalized logarithm transformed to
account for differences in metabolite abundance. Metabolites with a fold change >1.5 and $p <$
0.05 were considered to be significantly different for pathway analysis. Pathway analysis was
conducted using KEGG human metabolic pathways. Disease signature analysis was conducted
using metabolite sets reported in human blood.

Isolation of Enterocytes and Western blot analysis

Lumenal contents of the proximal intestine were flashed by PBS prior to evert them using bamboo sticks with pointed ends. Everted intestines were incubated in PBS with 1.5 mM EDTA solution for 20 min and released enterocytes were collected by centrifugation at 4°C at 500 x g for 5 min. Following two washes, the pellets were resuspended in lysis buffer (Tris-HCl, 137mM NaCl, 10% glycerol, 1% Triton X-100, 2 mM EDTA) with protease and phosphatase inhibitors (Thermo Scientific) added along with the PMSF (Sigma-Aldrich). During enterocyte separation, all the buffers were supplemented with protease inhibitors (AGScientific). Solubilized proteins were separated by 10% SDS-PAGE. Visualization was done by chemiluminescence (SuperSignal, Thermo Fisher) and digital imaging (Protein Simple). Rabbit anti-mouse ZIP14 antibody was custom made by Genscript. Antibodies for ZIP4, ZnT1, and GAPDH were obtained from Proteintech (20625), Novusbio (BP-94196), and Cell Signaling (14C10), respectively.

Statistical Analyses

Data are presented as means ± SE. Significance was assessed by Student's t-test for single comparisons. Statistical significance was set at $P < 0.05$. Analyses were performed using GraphPad Prism. The statistical criteria for metabolomics analysis and 16S rRNA gene sequencing analysis were included in the methods.

References

1. Present Knowledge in Nutrition - 11th Edition. Available at: https://www.elsevier.com/books/present-knowledge-in-nutrition/marriott/978-0-323-66162-1. (Accessed: 23rd June 2021)

2. King, J. C., Shames, D. M. & Woodhouse, L. R. Zinc homeostasis in humans. *J. Nutr.* **130**, 1360S–6S (2000).

3. Cousins, R. J. Theoretical and practical aspects of zinc uptake and absorption. *Adv. Exp. Med. Biol.* **249**, 3–12 (1989).

4. Hoadley, J. E., Leinart, A. S. & Cousins, R. J. Kinetic analysis of zinc uptake and serosal transfer by vascularly perfused rat intestine. *Am. J. Physiol. Liver Physiol.* **252**, G825–G831 (1987).

5. McMahon, R. J. & Cousins, R. J. Regulation of the zinc transporter ZnT-1 by dietary zinc. *Proc. Natl. Acad. Sci.* **95**, 4841–4846 (1998).

6. Guthrie, G. J. *et al.* Influence of ZIP14 (slc39A14) on intestinal zinc processing and barrier function. *Am. J. Physiol. Gastrointest. Liver Physiol.* **308**, G171-8 (2015).

7.   Dufner-Beattie, J., Langmade, S. J., Wang, F., Eide, D. & Andrews, G. K. Structure,
function, and regulation of a subfamily of mouse zinc transporter genes. *J. Biol. Chem.*
278, 50142–50 (2003).

8.   Liuzzi, J. P., Bobo, J. A., Cui, L., McMahon, R. J. & Cousins, R. J. Zinc transporters 1, 2
and 4 are differentially expressed and localized in rats during pregnancy and lactation. *J.*
Nutr. **133**, 342–51 (2003).

9.   Dufner-Beattie, J., Kuo, Y.-M., Gitschier, J. & Andrews, G. K. The adaptive response to
dietary zinc in mice involves the differential cellular localization and zinc regulation of the
zinc transporters ZIP4 and ZIP5. *J. Biol. Chem.* **279**, 49082–90 (2004).

10. Ohashi, W. & Fukada, T. Contribution of zinc and zinc transporters in the pathogenesis of
inflammatory bowel diseases. *Journal of Immunology Research* **2019**, (2019).

11. Geiser, J., Venken, K. J. T., de Lisle, R. C. & Andrews, G. K. A mouse model of
acrodermatitis enteropathica: Loss of intestine zinc transporter ZIP4 (Slc39a4) disrupts
the stem cell niche and intestine integrity. *PLoS Genet.* **8**, (2012).

12. Ohashi, W. *et al.* Zinc Transporter SLC39A7/ZIP7 Promotes Intestinal Epithelial Self-
Renewal by Resolving ER Stress. *PLOS Genet.* **12**, e1006349 (2016).

13. Podany, A. B., Wright, J., Lamendella, R., Soybel, D. I. & Kelleher, S. L. ZnT2-Mediated
Zinc Import Into Paneth Cell Granules Is Necessary for Coordinated Secretion and
Paneth Cell Function in Mice. *CMGH* **2**, 369–383 (2016).

14. Li, D. *et al.* A Pleiotropic Missense Variant in SLC39A8 Is Associated With Crohn's
Disease and Human Gut Microbiome Composition. *Gastroenterology* **151**, 724–732
(2016).

15. Sunuwar, L. *et al.* Pleiotropic ZIP8 A391T implicates abnormal manganese homeostasis
in complex human disease. *JCI Insight* **5**, (2020).

16. Nakata, T. *et al.* A missense variant in SLC39A8 confers risk for Crohn's disease by
disrupting manganese homeostasis and intestinal barrier integrity. *Proc. Natl. Acad. Sci.*
U. S. A. **117**, 28930–28938 (2020).

17. Girijashanker, K. *et al.* Slc39a14 gene encodes ZIP14, a metal/bicarbonate symporter:
similarities to the ZIP8 transporter. *Mol. Pharmacol.* **73**, 1413–23 (2008).

18. Aydemir, T. B., Troche, C., Kim, M.-H. & Cousins, R. J. Hepatic ZIP14-mediated Zinc
Transport Contributes to Endosomal Insulin Receptor Trafficking and Glucose
Metabolism. *J. Biol. Chem.* **291**, 23939–23951 (2016).

19. Troche, C., Aydemir, T. B. & Cousins, R. J. Zinc transporter Slc39a14 regulates
inflammatory signaling associated with hypertrophic adiposity. *Am. J. Physiol. Endocrinol.*

Metab. **310**, ajpendo.00421.2015 (2015).

20.   Aydemir, T. B. *et al.* Zinc Transporter ZIP14 Functions in Hepatic Zinc, Iron and Glucose

Homeostasis during the Innate Immune Response (Endotoxemia). *PLoS One* **7**, e48679

(2012).

21.   Aydemir, T. B. & Cousins, R. J. The Multiple Faces of the Metal Transporter ZIP14

(SLC39A14). *J. Nutr.* **148**, 174–184 (2018).

22.   Aydemir, T. B. *et al.* Metal Transporter *Zip14* (*Slc39a14*) Deletion in Mice Increases

Manganese Deposition and Produces Neurotoxic Signatures and Diminished Motor

Activity. *J. Neurosci.* **37**, 5996–6006 (2017).

23.   Aydemir, T. B. *et al.* Intestine-specific deletion of metal transporter Zip14 (Slc39a14)

causes brain manganese overload and locomotor defects of manganism. *Am. J. Physiol.*

- Gastrointest. Liver Physiol. **318**, G673–G681 (2020).

24.   Starke, I. C., Pieper, R., Neumann, K., Urgen Zentek, J. & Vahjen, W. The impact of high

dietary zinc oxide on the development of the intestinal microbiota in weaned piglets.

doi:10.1111/1574-6941.12233

25.   Festi, D. *et al.* Gut microbiota and metabolic syndrome. *World J. Gastroenterol.* **20**,

16079 (2014).

26.   Lopez, C. A. & Skaar, E. P. Cell Host & Microbe The Impact of Dietary Transition

Metals on Host-Bacterial Interactions. *Cell Host Microbe* **23**, 737–748 (2018).

27.   KL, G., BP, A. & EMM, Q. The microbiome and inflammatory bowel disease. *J. Allergy*

Clin. Immunol. **145**, 16–27 (2020).

28.   Morgan, X. C. *et al.* Dysfunction of the intestinal microbiome in inflammatory bowel

disease and treatment. *Genome Biol. 2012 139* **13**, 1–18 (2012).

29.   Yow, G. Y., Uo, T., Yoshimura, T. & Esaki, N. D-Amino acid-N-acetyltransferase of

Saccharomyces cerevisiae: A close homologue of histone acetyltransferase Hpa2p acting

exclusively on free D-amino acids. *Arch. Microbiol.* **182**, 396–403 (2004).

30.   Sampath, V. *et al.* Biochemical characterization of Hpa2 and Hpa3, two small closely

related acetyltransferases from saccharomyces cerevisiae. *J. Biol. Chem.* **288**, 21506–

21513 (2013).

31.   Pang, Z. *et al.* MetaboAnalyst 5.0: narrowing the gap between raw spectra and functional

insights. *Nucleic Acids Res.* (2021). doi:10.1093/nar/gkab382

32.   Wang, M. *et al.* Metabonomic strategy for the detection of metabolic effects of probiotics

combined with prebiotic supplementation in weaned rats†. *RSC Adv.* **8**, 5042–5057

(2018).

33.   Küry, S. *et al.* Identification of SLC39A4, a gene involved in acrodermatitis enteropathica.
429   *Nat. Genet.* **31**, 239–40 (2002).

430   34.   Aydemir, T. B. *et al.* Metal transporter Zip14 (Slc39a14) deletion in mice increases
431   manganese deposition and produces neurotoxic signatures and diminished motor activity.
432   *J. Neurosci.* **37**, (2017).

433   35.   Jenkitkasemwong, S. *et al.* SLC39A14 Is Required for the Development of Hepatocellular
434   Iron Overload in Murine Models of Hereditary Hemochromatosis. *Cell Metab.* **22**, 138–
435   150 (2015).

436   36.   Erdman, J. W., MacDonald, I. A. & Zeisel, S. H. *Present Knowledge in Nutrition: Tenth*
437   *Edition. Present Knowledge in Nutrition: Tenth Edition* (Wiley-Blackwell, 2012).
438   doi:10.1002/9781119946045

439   37.   Ross, A. C., Caballero, B. H., Cousins, R. J., Tucker, K. L. & Ziegler, T. R. *Modern*
440   *nutrition in health and disease.* (Wolters Kluwer Health/Lippincott Williams & Wilkins,
441   2014).

442   38.   WHO. The World health report: 2002: Reducing the risks, promoting healthy life. *Therapie*
443   **52**, 569–571 (2002).

444   39.   Skrovanek, S. Zinc and gastrointestinal disease. *World J. Gastrointest. Pathophysiol.* **5**,
445   496–513 (2014).

446   40.   Ross, A. Catharine, Cousins, Robert J. and Caballero, B. et. al. *Modern Nutrition in*
447   *Health and Disease - Wolters Kluwer Health, Lippincott Williams & Wilkins - Literati*
448   *by Credo.* (2014).

449   41.   Zackular, J. P. *et al.* Dietary zinc alters the microbiota and decreases resistance to
450   Clostridium difficile infection. *Nat. Med.* **22**, 1330–1334 (2016).

451   42.   Yu, T. *et al.* Dietary high zinc oxide modulates the microbiome of ileum and colon in
452   weaned piglets. *Front. Microbiol.* **8**, 825 (2017).

453   43.   Reed, S. *et al.* Chronic zinc deficiency alters chick gut microbiota composition and
454   function. *Nutrients* **7**, 9768–9784 (2015).

455   44.   Donia, M. S. & Fischbach, M. A. Small Molecules from the Human Microbiota.
456   doi:10.1126/science.1254766

457   45.   Krautkramer, K. A., Fan, J. & Bäckhed, F. Gut microbial metabolites as multi-kingdom
458   intermediates. *Nat. Rev. Microbiol.* **19**, (2021).

459   46.   Wikoff, W. R. *et al.* Metabolomics analysis reveals large effects of gut microflora on
460   mammalian blood metabolites. *Proc. Natl. Acad. Sci. U. S. A.* **106**, 3698–3703 (2009).

47.   Roager, H. M. & Licht, T. R. Microbial tryptophan catabolites in health and disease.

Nature Communications **9**, 1–10 (2018).

48. Agus, A., Planchais, J. & Sokol, H. Gut Microbiota Regulation of Tryptophan Metabolism
in Health and Disease. *Cell Host and Microbe* **23**, 716–724 (2018).

49. Eide, D. J. Homeostatic and adaptive responses to zinc deficiency in saccharomyces
cerevisiae. *J. Biol. Chem.* **284**, 18565–18568 (2009).

50. Siva, S., Rubin, D. T., Gulotta, G., Wroblewski, K. & Pekow, J. Zinc deficiency is
associated with poor clinical outcomes in patients with inflammatory bowel disease.
Inflamm. Bowel Dis. **23**, 152–157 (2017).

51. Chiaro, T. R. *et al.* A member of the gut mycobiota modulates host purine metabolism
exacerbating colitis in mice. *Sci. Transl. Med.* **9**, (2017).

52. Manocha, M. & Khan, W. I. Serotonin and GI disorders: An update on clinical and
experimental studies. *Clinical and Translational Gastroenterology* **3**, (2012).

53. Aydemir, T. B., Troche, C., Kim, M.-H. & Cousins, R. J. Hepatic ZIP14-mediated zinc
transport contributes to endosomal insulin receptor trafficking and glucose metabolism. *J.*
Biol. Chem. **291**, (2016).

54. Moro-García, M. A., Mayo, J. C., Sainz, R. M. & Alonso-Arias, R. Influence of
Inflammation in the Process of T Lymphocyte Differentiation: Proliferative, Metabolic, and
Oxidative Changes. *Front. Immunol.* **9**, 339 (2018).

55. Aydemir, T. B., Sitren, H. S. & Cousins, R. J. The zinc transporter Zip14 influences c-met
phosphorylation and hepatocyte proliferation during liver regeneration in mice.
Gastroenterology **142**, (2012).

56. Ramakrishnan, S. K. *et al.* Intestinal non-canonical NFκB signaling shapes the local and
systemic immune response. *Nat. Commun.* **10**, (2019).

57. Das, N. K. *et al.* Microbial Metabolite Signaling Is Required for Systemic Iron
Homeostasis. *Cell Metab.* **31**, 115-130.e6 (2020).

58. Iliev, I. D. *et al.* Interactions between commensal fungi and the C-type lectin receptor
dectin-1 influence colitis. *Science (80-.).* **336**, 1314–1317 (2012).

59. Jiang, T. T. *et al.* Commensal Fungi Recapitulate the Protective Benefits of Intestinal
Bacteria. *Cell Host Microbe* **22**, 809-816.e4 (2017).

60. Johnson, E. L. *et al.* Sphingolipids produced by gut bacteria enter host metabolic
pathways impacting ceramide levels. *Nat. Commun.* **11**, (2020).

61. Caporaso, J. G. *et al.* Global patterns of 16S rRNA diversity at a depth of millions of
sequences per sample. *Proc. Natl. Acad. Sci. U. S. A.* **108**, 4516–4522 (2011).

62. Callahan, B. J. *et al.* DADA2: High-resolution sample inference from Illumina amplicon

data. *Nat. Methods 2016 137* **13**, 581–583 (2016).

63.   McDonald, D. *et al.* An improved Greengenes taxonomy with explicit ranks for ecological and evolutionary analyses of bacteria and archaea. *ISME J. 2012 63* **6**, 610–618 (2011).

64.   McMurdie, P. J. & Holmes, S. phyloseq: An R Package for Reproducible Interactive Analysis and Graphics of Microbiome Census Data. *PLoS One* **8**, e61217 (2013).

65.   Oksanen, J. *et al.* Package 'vegan' Title Community Ecology Package Version 2.5-7. (2020).

66.   Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol.* **15**, 1–21 (2014).

67.   Chang, H. W. *et al.* Quantitative real time PCR assays for the enumeration of Saccharomyces cerevisiae and the Saccharomyces sensu stricto complex in human feces. *J. Microbiol. Methods* **71**, 191–201 (2007).

68.   Guthrie, G. J. G. J. G. J. *et al.* Influence of ZIP14 (slc39A14) on intestinal zinc processing and barrier function. *Am. J. Physiol. - Gastrointest. Liver Physiol.* **308**, G171–G178 (2015).

FIGURES.

Figure 1. Altered gastrointestinal Zn homeostasis in *Zip14* KO mice. Zn concentrations in gastrointestinal tissues (A) and the luminal contents (B) were measured by MP-AES. Values are means ± SE; n = 16-19 (both female and male mice were included). Student's t-test for WT vs. WB-KO comparison. C) Abundance of Zn transporters, ZIP14, ZIP4, and ZnT1, in isolated enterocytes was shown by western blot analysis.

Figure 2. Decreased gut microbial diversity in the WB-Zip14 KO mice. A, B) WB-Zip14 KO
displayed decreased α-diversity, as shown by 16S rRNA gene sequencing. Fold change of >2
and p-value < 0.05 were considered significantly different. C) The most significant changes at the
family and genus levels (WB-KO/WT) (n=7-8). The details of the analysis are provided in the
methods section.

Figure 3. The ZIP14-shaped microbiome can influence intestinal permeability and metabolic phenotypes in the host. A) Following three weeks of antibiotics treatment, mice have received a fecal transplant from either WT (WTCv) or WB-KO (KOCv) mice. B) Plasma FITC-Dextran concentrations were measured fluorometrically. B) Fasting blood glucose was measured by tail bleeding using the OneTouch® Ultra Blood glucose monitoring system. Percent body fat (C) and percent lean mass (D) were assessed by nuclear magnetic resonance. Values are means ± SE; n = 5-7 (both female and male mice were included). Student's t-test.

Figure 4. Serum untargeted metabolomics profiling of *Zip14* KO and WT mice. Serum metabolites were measured Gas chromatography (GC) coupled to time-of-flight mass spectrometry (TOF-MS) (n=6 per group). A) The PCA score plot of serum samples from WT and WB-KO mice. B) Volcano plot. C) The serum metabolites with the known identity were statistically different. D) S. Cerevisiae DNA was quantified by qPCR in colonic digesta from either WT and WB-KO or WT mice that received fecal transplant either from WT (WTCv) or KO (KOCv) mice. Values are means ± SE; n = 3. Student's t-test. E) Following ten days of antifungal (fluconazole) treatment, plasma FITC-Dextran concentrations were measured fluorometrically. Values are means ± SE; n = 6-9. Student's t-test.

Figure 5.. Pathway and enrichment analyses using MetaboAnalyst. For the significantly different metabolites (details in method section), pathway and enrichment analyses were conducted using MetaboAnalyst.   A) Pathway analysis was conducted using KEGG human metabolic pathways.   B) Disease signature analysis was conducted using metabolite sets reported in human blood.

Figure 6. Altered energy metabolism in the WB-KO mice. Following 2-3 days of acclimation,
metabolic parameters of the mice were measured by the Comprehensive Laboratory Animal
Monitoring System (CLAMS). Measurements of VO2 (A) and VCO2 (B) gas exchanges were
collected for five days. C)The respiratory exchange rate (RER) was obtained based on these
values. Values are means ± SE; n= 4 (both female and male mice were included). Student t-test.

Figure 7. Model for a mechanism of intestinal permeability in *Zip14* KO mice. Deletion of the host gene encoding metal transporter, *Slc39a14/Zip14*, generates Zn-deficient epithelial and luminal content in the intestine. Reduced Zn concentrations in the enterocytes were shown to dysregulate tight junction proteins (TJP), subsequently increasing intestinal permeability [68]. Reduced Zn concentrations in the lumen lower bacterial diversity and give the opportunity to *S. cerevisiae* overgrowth, further contributing to intestinal permeability. Consequently, altered host and microbial metabolites, inflammation, and shift in energy metabolism are found in the host.

589